Related Experiment Video
Updated: May 12, 2026
12:45
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
Extended lymphadenectomy in rectal cancer is debatable
Marco E Allaix1, Alessandro Fichera
1Department of Surgery, Pritzker School of Medicine, University of Chicago, 5841 S. Maryland Ave, MC 5095, Chicago, IL 60637, USA. mallaix@surgery.bsd.uchicago.edu
World Journal of Surgery
|April 10, 2013
Summary
Neoadjuvant combined modality therapy and total mesorectal excision have significantly improved rectal cancer outcomes. Consequently, extended lymph node dissection is now rarely necessary in rectal cancer surgery.
Area of Science:
- Oncology
- Surgical Oncology
- Gastrointestinal Surgery
Background:
- Rectal cancer treatment has evolved significantly.
- Neoadjuvant therapies aim to improve surgical outcomes.
- Total mesorectal excision is a standard surgical technique.
Purpose of the Study:
- To evaluate the current role of extended lymph node dissection in rectal cancer surgery.
- To determine if extended lymph node dissection offers additional benefits beyond standard treatment protocols.
Main Methods:
- Review of current treatment guidelines and clinical evidence.
- Analysis of outcomes data comparing different surgical approaches for rectal cancer.
Main Results:
- Neoadjuvant combined modality therapy has led to major improvements in local control.
- Total mesorectal excision has enhanced survival rates.
- Extended lymph node dissection plays a very limited role due to these advancements.
Conclusions:
- The benefits of neoadjuvant therapy and total mesorectal excision have minimized the need for extended lymph node dissection.
- Current treatment strategies for rectal cancer prioritize less invasive approaches with proven efficacy.
